His executive leadership experience spans across operations, business development, sales, marketing, Six Sigma, manufacturing, and corporate accounts.ĭuring his tenure at Spectrum, Mr. Throughout his career he has successfully integrated leadership and strategy to create meaningful value. He has leadership experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen Inc. He has over 20 years of diverse pharmaceutical leadership experience. Riga was named Spectrum’s President and Chief Executive Officer on January 1st, 2022. Thomas Riga is Spectrum’s President and Chief Executive Officer. in Business Administration from the University of Missouri. Bradrick holds an MBA from the Johnson Graduate School of Management at Cornell University and a B.S. Bradrick began her career as a Federal Reserve Bank Examiner. Bradrick was an investment banker for the life sciences sector at Piper Jaffray, Credit Suisse, and Chase Securities for 10 years. She previously served in strategy and corporate development positions for 10 years at Insulet Corporation as Vice President, Strategy & Corporate Development and at Abbott Diabetes Care as the Head of Global Business Development. Bradrick was Chief Operating Officer and Chief Financial Officer at ViaCyte. She has 25 years of experience in finance, strategy, and corporate development for life science companies, with both operational and advisory experience. Bradrick is currently the Chief Financial Officer at Neurelis, Inc., a commercial stage neuroscience company. In addition, he has served on the boards of the National Osteoporosis Foundation, Friends of the National Library of Medicine, and is a Commissioner on the Medical Representatives National Certification Commission.īrittany K. He previously served on the boards of Sucampo Pharmaceuticals and Galena Bio Pharma. Ashton currently serves on the board of a publicly traded company, Recro Pharma. Ashton has been a principal at Harrison Consulting Group, LLC, a privately held biopharmaceutical consulting firm with expertise in commercialization, payer strategy, and reimbursement. This unit has responsibility for the sales and marketing to Amgen's largest customer base including health systems, managed care organizations, commercial and government payers, distribution channels, GPO’s and the corporate pricing group. He also served as Vice President/General Manager of the Corporate Accounts, Business Unit. While with Amgen he served in various positions including Vice President of U.S. Ashton has retired from an extensive career at Amgen Inc. William Ashton is a former Fortune 100 senior executive with over 40 years’ experience in the biotechnology and pharmaceutical business.
0 kommentar(er)
